MHRA grants selpercatinib (Retsevmo) conditional marketing authorisation for the treatment of RET fusion-positive advanced lung cancer and thyroid cancer.

Authorisation is based LIBRETTO-00 Phase I/II trial, a single-arm study of over 700 patients with RET-driven cancers. Of 105 previously treated patients with NSCLC, 64% had a response as did 69.1% of 55 previously treated patients with RET-mutant medullary thyroid cancer.

Source:

PharmaTimes